CAH insider sale notice: 21,367 shares via Merrill Lynch on 08/20/2025
Rhea-AI Filing Summary
Cardinal Health (CAH) Form 144 notice reports a proposed sale of 21,367 common shares through Merrill Lynch on 08/20/2025 with an aggregate market value of $3,216,330.00. The filing shows the shares were acquired on 08/15/2025 from Cardinal Health, Inc. as 13,088 shares from performance stock vesting and 8,279 shares from restricted stock vesting. No securities were reported sold by the same person in the past three months. The document includes the required representation that the seller is not aware of undisclosed material adverse information and references potential Rule 10b5-1 plan considerations.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale notice for newly vested equity; documents compliance with Rule 144 disclosure requirements.
The Form 144 notifies the brokered sale of 21,367 newly vested Cardinal Health common shares, specifying the vesting dates and vesting types (performance and restricted stock). The filing identifies the broker (Merrill Lynch) and the proposed sale date (08/20/2025). From a transactions perspective this is a standard disclosure enabling a registered broker to effect a sale under Rule 144; it does not itself confirm execution of the sale or indicate other material corporate developments.
TL;DR: Disclosure meets procedural requirements; raises routine governance considerations around timing and trading plans.
The filer represents no undisclosed material adverse information and the form references Rule 10b5-1 plan adoption or instructions as applicable. The details provided (acquisition by vesting on 08/15/2025, proposed sale on 08/20/2025, broker identified) are consistent with standard insider liquidity events following equity award vesting. The filing is informational; any governance implications depend on context not provided here (e.g., existence and adoption date of a trading plan).